Axillary Dissection Versus No Axillary Dissection in Elderly Patients with Breast Cancer and No Palpable Axillary Nodes: Results After 15 Years of Follow-UpGabriele Martelli, Roberto Agresti, Rosalba Miceli et al.|Annals of Surgical Oncology|2010Cited by 172
Has the Outcome for Patients Who Undergo Resection of Primary Retroperitoneal Sarcoma Changed Over Time? A Study of Time Trends During the Past 15 yearsDario Callegaro, Carol J. Swallow, Eberhard Stoeckle et al.|Annals of Surgical Oncology|2020Cited by 56
Longitudinal prognostication in retroperitoneal sarcoma survivors: Development and external validation of two dynamic nomogramsDario Callegaro, Alessandro Gronchi, Francesco Barretta et al.|European Journal of Cancer|2021Cited by 32
Myeloablative doses of yttrium‐90‐ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemiaAnna Guidetti, Alessandro M. Gianni, Carmelo Carlo‐Stella et al.|Cancer|2011Cited by 28
The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Yttrium-90 Ibritumomab Tiuxetan Is Analogous to That Observed Following High-Dose Chemotherapy: a Matched-Pair Analysis In Non-Hodgkin Lymphoma Patients.Anna Guidetti, Alessandro M. Gianni, Carmelo Carlo‐Stella et al.|Blood|2010Cited by 1